Atea Pharmaceuticals Inc. (AVIR) Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting Did Not Meet the Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/6/2026

1. MU
2. APTX:CN
3. IQMX
4. SPY
5. EROC
6. MSTR
7. SEER
8. FRBT
9. MSFT
10. USO

Go back to Atea Pharmaceuticals Inc. (AVIR) Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting Did Not Meet the Primary Endpoint

Atea Pharmaceuticals (AVIR) Strong Sell-Off 'Premature' - William Blair

October 19, 2021 10:55 AM EDT

William Blair analyst Tim Lugo reiterated an Outperform rating and {REMOVEPT} price target on Atea Pharmaceuticals (NASDAQ: AVIR) amid today's sell-off, calling it "premature."

The analyst commented, "While the top-line miss in the Phase II MOONSONG study is a setback for Atea, we... More

Atea Pharmaceuticals Inc. (AVIR) to Resume Trading at 7:30 a.m.

October 19, 2021 7:10 AM EDT

Atea Pharmaceuticals Inc. (NASDAQ: AVIR) to Resume Trading at 7:30 a.m.

... More

Merck (MRK) Strength Pre-Open Tied to Atea Pharmaceuticals Inc. (AVIR) Trial Missing Primary Endpoint

October 19, 2021 7:09 AM EDT

Merck (NYSE: MRK) Strength Pre-Open Tied to Atea Pharmaceuticals Inc. (NASDAQ: AVIR) Trial Missing Primary Endpoint

Merck up 2.2%, Atea Still Halted... More